U.S. NCI issues guidance for deliberations on rare cancer trial closures
On 22 May 2012, the U.S. National Cancer Institute (NCI) Office of Cancer Centres has published the following announcement on the NCI Website
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
On 22 May 2012, the U.S. National Cancer Institute (NCI) Office of Cancer Centres has published the following announcement on the NCI Website
To speed progress against cancer and other diseases, the St. Jude Children’s Research Hospital – Washington University Paediatric Cancer Genome Project announced the largest-ever release of comprehensive human cancer genome data for free access by the global scientific community in order to help researchers everywhere speed discoveries.
First volume of the Cancer Cell Line Encyclopaedia catalogues the world’s cancer cell lines
Launch of Call to Action to improve patient care by enabling access to personalised medicine in Europe
Thousands of patients with rare forgotten cancers are paying a high price because doctors lack awareness of their conditions
4th ESMO Conference on Sarcoma and GIST
Joint ESMO/Rare Cancers Europe conference explores ways to improve clinical research on rare cancers
International Childhood Cancer Day: Calls for policy changes as lives put at risk by bureaucracy
The EORTC has joined forces with Cancer Research UK, the National Institute for Health Research Cancer Research Network (NCRN), and the United States National Cancer Institute (NCI) to launch an initiative to boost the development of new treatments for patients with rare cancers.
On 24 October 2011, during the third meeting of the European Union Committee of Experts on Rare Diseases (EUCERD), the Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States were unanimously adopted by the 51-member EUCERD, which has representatives from all 27 EU Member States and from all domains relevant to the fields of rare diseases and orphan drugs, including academia, government, the biopharmaceutical industry and patient organisations.
On 24 September 2011, the 2011 European Multidisciplinary Cancer Congress, held from 23-27 September 2011 in Stockholm, Sweden, organised the first-ever patient advocacy/ethics session dedicated specifically to rare cancers.
At the occasion of the 2011 European Multidisciplinary Cancer Congress held from 23-27 September 2011 in Stockholm, Sweden, the European Action Against Rare Cancers initiative presented its new name and logo, Rare Cancers Europe, as well as its new tagline: Joining forces for action.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.